Loading patent…
AssigneesGenentech, Inc., Foundation Medicine, Inc.
InventorsChristiaan Nicolaas KLIJN, James LEE, David Hugh STOKOE, Robert GENTLEMAN, Florian GNAD, Leonard David GOLDSTEIN, Juliann CHMIELECKI, Ryan J. HARTMAIER
Estimating the term…
The invention provides methods of identifying a subject having cancer, such as lung cancer, by analyzing expression levels of one or more NRF2 splice variants or NRF2 target genes. The invention also provides methods of treating cancer in a subject with a NRF2 pathway antagonist, wherein the subject expresses one or more NRF2 splice variants or overexpresses one or more NRF2 target genes.
A method of diagnosing a cancer in a subject, the method comprising:
3-8. (canceled)
10-11. (canceled)
14-15. (canceled)
(canceled)
(canceled)
21-32. (canceled)
34-40. (canceled)
A method of treating a subject having a cancer, the method comprising administering to the subject a therapeutically effective amount of a NRF2 pathway antagonist, wherein the expression level of each of the following 27 genes AKR1B10, AKR1C2, SRXN1, OSGIN1, FECH, GCLM, TRIM16, ME1, KYNU, CABYR, SLC7A11, TRIM16L, AKR1C4, CYP4F11, RSPO3, ABCC2, AKR1B15, NR0B1, UGDH, TXNRD1, GSR, AKR1C3, TALDO1, PGD, TXN, NQO1, and FTL in a sample obtained from the subject has been determined to be increased relative to a respective reference expression level of each of the 27 genes.
42-47. (canceled)
49-50. (canceled)
52-53. (canceled)
55-56. (canceled)
(canceled)
60-78. (canceled)
(canceled)
Dependencies are inferred from the claim text.